MX2023005032A - Anticuerpos para tratamientos con opioides. - Google Patents

Anticuerpos para tratamientos con opioides.

Info

Publication number
MX2023005032A
MX2023005032A MX2023005032A MX2023005032A MX2023005032A MX 2023005032 A MX2023005032 A MX 2023005032A MX 2023005032 A MX2023005032 A MX 2023005032A MX 2023005032 A MX2023005032 A MX 2023005032A MX 2023005032 A MX2023005032 A MX 2023005032A
Authority
MX
Mexico
Prior art keywords
antibodies
opioid
treat
pharmaceutical compositions
opioid treatments
Prior art date
Application number
MX2023005032A
Other languages
English (en)
Spanish (es)
Inventor
Kim D Janda
Paul T Bremer
Bin Zhou
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2023005032A publication Critical patent/MX2023005032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023005032A 2020-11-10 2021-11-08 Anticuerpos para tratamientos con opioides. MX2023005032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063111699P 2020-11-10 2020-11-10
PCT/US2021/058459 WO2022103700A1 (en) 2020-11-10 2021-11-08 Antibodies for opioid treatments

Publications (1)

Publication Number Publication Date
MX2023005032A true MX2023005032A (es) 2023-05-16

Family

ID=81601678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005032A MX2023005032A (es) 2020-11-10 2021-11-08 Anticuerpos para tratamientos con opioides.

Country Status (10)

Country Link
US (1) US20230399418A1 (https=)
EP (1) EP4244256A4 (https=)
JP (1) JP7839789B2 (https=)
KR (1) KR20230107301A (https=)
CN (1) CN116745318A (https=)
AU (1) AU2021377609A1 (https=)
CA (1) CA3200523A1 (https=)
IL (1) IL302673A (https=)
MX (1) MX2023005032A (https=)
WO (1) WO2022103700A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3267132A1 (en) * 2022-09-09 2024-03-14 Regents Of The University Of Minnesota ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808822A (en) * 2006-04-14 2008-02-16 Amgen Inc Erythropoietin receptor agonists
WO2013095091A2 (en) * 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
AU2017345786B2 (en) * 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF

Also Published As

Publication number Publication date
WO2022103700A1 (en) 2022-05-19
CN116745318A (zh) 2023-09-12
KR20230107301A (ko) 2023-07-14
US20230399418A1 (en) 2023-12-14
EP4244256A4 (en) 2024-12-25
AU2021377609A1 (en) 2023-06-08
IL302673A (en) 2023-07-01
CA3200523A1 (en) 2022-05-19
JP2023548603A (ja) 2023-11-17
AU2021377609A9 (en) 2024-09-26
JP7839789B2 (ja) 2026-04-02
EP4244256A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2017002904A1 (es) Métodos y kits para tratar la depresión
BR112022012106A2 (pt) Inibidores de sos1
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
MX2021013640A (es) Composiciones novedosas y metodos.
CL2019000268A1 (es) Composición de cannabis.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
MX389702B (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
NI201600021A (es) Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso
MX2018016332A (es) Quimioterapias de combinacion.
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
MX2017009122A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
CL2020003306A1 (es) Composiciones bifuncionales para el tratamiento del cáncer.
CO2022000270A2 (es) Inhibidores de enzimas
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CO2020007129A2 (es) Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas